1. Berard L, Antonishyn N, Arcudi K, et al. Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. Diabetes Ther. 2018;9(2):501–19.
2. Han Cho N. IDF Diabetes Atlas 2019. International Diabetes Federation. 2019. 1 p. https://idf.org/e-library/epidemiology-research/diabetes-atlas.
3. Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25–33. http://dx.doi.org/10.1016/S2213-8587(18)30303-6
4. PERKENI. Pedoman Petunjuk Praktis Terapi Insulin Pada Pasien Diabetes Mellitus 2021. Pb Perkeni. 2021;32–9.
5. Cheng AYY, Patel DK, Reid TS, Wyne K. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Adv Ther. 2019;36(5):1018–30. https://doi.org/10.1007/s12325-019-00925-6
6. Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr Rev. 2020 Oct 1;41(5):733–55. doi: 10.1210/endrev/bnaa015. PMID: 32396624; PMCID: PMC7366348.
7. Buse JB, Davies MJ, Frier BM, Philis-Tsimikas A. 100 years on: The impact of the discovery of insulin on clinical outcomes. BMJ Open Diabetes Res Care. 2021;9(1).
8. Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53(1):998–1009. https://doi.org/10.1080/07853890.2021.1925148
9. Galstyan Gr, Bhansali A, Vargas-Uricoechea H, et al. 1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study. Diabetes. 2020 Jun 1;69(Supplement_1):1028-P. https://doi.org/10.2337/db20-1028-P
10. Sethi B, Alrubeaan K, Unubol M, et al. 737-P: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes Mellitus (T2DM) Uncontrolled on Basal Insulins (BI): ARTEMIS-DM Study. Diabetes. 2021 Jun 1;70(Supplement_1):737-P. https://doi.org/10.2337/db21-737-P
11. Ji L, Bi Y, Ye S, Huang Y, et al. Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies. Diabetes Res Clin Pract. 2021;176:108848. https://doi.org/10.1016/j.diabres.2021.108848
12. Ghosh S, Ghosh R. Glargine-300: An updated literature review on randomized controlled trials and real-world studies. World J Diabetes. 2020;11(4):100–14.
13. Garber AJ, Handelsman Y, Grunberger G, Eet al. Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–39.
14. KEMENKES RI. Keputusan Menteri Kesehatan RI Nomor HK.01.07/MENKES/6485/2021 Tentang Formularium Nasional. 2021;18–28.
15. Care D, Suppl SS. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2021. Diabetes Care. 2021;44(January):S111–24.
16. Castellana M, Procino F, Sardone R, et al. Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: A meta-analysis of randomized controlled trials. BMJ Open Diabetes Res Care. 2020;8(1):1–8.
Facebook
Masuk dengan Email
